Substitution of a Nonnucleoside Reverse Transcriptase Inhibitor for a Protease Inhibitor in the Treatment of Patients with Undetectable Plasma Human Immunodeficiency Virus Type 1 RNA | Zendy

François Raffi | Zendy; Benjamin Bonnet | Zendy; Valentine Marie Ferré | Zendy; J.-L. Esnault | Zendy; Philippe Van de Perre | Zendy; Véronique Reliquet | Zendy; S Léautez | Zendy; C. Bouillant | Zendy; O. Vergnoux | Zendy; P. Weinbreck | Zendy

Open Access

Substitution of a Nonnucleoside Reverse Transcriptase Inhibitor for a Protease Inhibitor in the Treatment of Patients with Undetectable Plasma Human Immunodeficiency Virus Type 1 RNA

Author(s) -

François Raffi,

Benjamin Bonnet,

Valentine Marie Ferré,

J.-L. Esnault,

Philippe Van de Perre,

Véronique Reliquet,

S Léautez,

C. Bouillant,

O. Vergnoux,

P. Weinbreck

Publication year - 2000

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/317424

Subject(s) - protease inhibitor (pharmacology) , reverse transcriptase inhibitor , medicine , regimen , reverse transcriptase , viral load , virology , protease , confidence interval , gastroenterology , virus , sida , viral disease , antiretroviral therapy , biology , rna , enzyme , biochemistry , gene

Seventy-three patients infected with human immunodeficiency virus type 1 (HIV-1) were enrolled in a prospective observational study to investigate the efficacy and tolerance of substituting a nonnucleoside reverse transcriptase inhibitor (NNRTI) for a protease inhibitor (PI) in patients whose plasma viral load (pVL) was controlled by a PI regimen. After a median follow-up of 52 weeks, 63 patients (86.3%) had undetectable pVLs. The incidence of virological breakthrough at 12 months of follow-up was 6.5% (95% confidence interval [CI], 1-20) among patients who had been antiretroviral naive before receiving HAART and 19.2% (95% CI, 6-34) among patients who had been treated with antiretroviral drugs before receiving the PI regimen (P=.10).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research